REVIEW
|
doi:10.20944/preprints201902.0043.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
ADC; HM2-MMAE; (vic-)trastuzumab duocarmazine; Trastuzumab deruxtecan; TAK-522; Trastuzumab emtansine; anti-HER2/PBD-MA; HER2 low; HER2-low; mode of action
Online: 4 February 2019 (17:01:31 CET)